Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)

The summary for the Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1): The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimental cancer therapeutics by merging the Phase 2 clinical trials program with the Experimental Therapeutics Clinical Trials Network (ETCTN, funded through RFA-CA-13-006) that is currently focused on Phase 1 clinical trials.

The FOA invites revision applications from ETCTN UM1 awardees to expand the scope of activities by adding capabilities to conduct Phase 2 clinical trials. The goal is to integrate Phase 2 infrastructure and expertise to create a unified network for an efficient and comprehensive conduct of early clinical trials. This integration of the Phase 2 capabilities into the new ETCTN structure will allow for more seamless advancement of experimental agents through early stages of development. Ultimately, the expected increased efficiency of clinical trial management is expected to accelerate the delivery of new cancer therapies to the public.
Federal Grant Title: Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-15-501
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.395
CFDA Descriptions: Cancer Treatment Research
Current Application Deadline: Jun 19, 2015
Original Application Deadline: Jun 19, 2015
Posted Date: Mar 23, 2015
Creation Date: Mar 23, 2015
Archive Date: Jul 20, 2015
Total Program Funding: $7,200,000
Maximum Federal Grant Award: $560,000
Minimum Federal Grant Award: none
Expected Number of Awards: 10
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public and State controlled institutions of higher education
Private institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following:
Only current ETCTN UM1 awardees may submit revision applications invited by this FOA (including Canadian recipients of the ETCTN award). See full announcement for full details.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-501.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Limited Competition: Pediatric Brain Tumor Consortium (UM1 Clinical Trials Required)
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health ...
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health ...
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognit...
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognit...
Breast and Prostate Cancer Data Quality and Patterns of Care Study
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2019 FederalGrants.com